For the first time, the MHRA made public a summary of the review that this decision was based on, including both efficacy and safety data for all of the trials, regardless of whether they had previously been published or not. This was important because about half of the trials had not been published in peer-reviewed journals.
为此，英国医药与健康产品管理委员会(MHRA)第一次公布了一份调查摘要，申明此决定是在评估了所有案例的功效性和安全性数据之后作出的，无论这些数据曾经被公布与否。这一点相当争议颇多，因为有近一半的案例没有在同类医学期刊中出现过。